Previous 10 | Next 10 |
908 Devices, Inc. (MASS) Q1 2022 Earnings Conference Call May 10, 2022 08:30 ET Company Participants Kelly Gura - Investor Relations Kevin Knopp - Chief Executive Officer & Co-Founder Joe Griffith - Chief Financial Officer Conference Call Participants Puneet Souda - SVB Securities Dan Ari...
908 Devices press release (NASDAQ:MASS): Q1 GAAP EPS of -$0.30. Revenue of $8.31M (+50.0% Y/Y). Outlook: 908 Devices continues to expect full year 2022 revenue to be in the range of $52 million to $55 million, representing 23% to 30% growth over full year 2021. For further details see: ...
Q1 2022 revenue increases 50% over prior year with Desktop revenue in BioPharma growing 68% 908 Devices Inc. (Nasdaq: MASS), a pioneer of purpose-built handheld and desktop mass spec devices for chemical and biomolecular analysis, today reported financial results for the qua...
908 Devices (NASDAQ:MASS) is scheduled to announce Q1 earnings results on Tuesday, May 10th, before market open. The consensus EPS Estimate is -$0.30 (-36.4% Y/Y) and the consensus Revenue Estimate is $7.65M (+38.1% Y/Y). Over the last 3 months, EPS estimates have seen 0 upward revisions and ...
ACRS, AFCG, AGEN, AHCO, ALGM, AMRS, ANIP, ARMK, AROC, ARVL, ATNX, AUPH, AVYA, AZEK, OTCPK:BAYZF, BCO, BHC, BLDE, BLDR, BSY, CCO, CEVA, CHH, CMPS, CRNC, CRON, DBD, DCTH, DM, DS, EBIX, ENOV, EOSE, EPC, EPZM, EVRI, FOX, FOXA, GMDA, H, HAE, HL, IAA, IGT, IIVI, IMUX, ITCI, JAGX, OTCPK:KEYUF, KNBE,...
Updates include new capabilities for iOS devices and expanded drug target list 908 Devices Inc. (Nasdaq: MASS), a pioneer of purpose-built handheld and desktop mass spec devices for chemical and biomolecular analysis, today announced updates to its MX908 handheld mass ...
Focus is on improving biotherapeutic process monitoring and control 908 Devices (Nasdaq: MASS), a pioneer of purpose-built handheld and desktop devices for chemical and biomolecular analysis, is partnering with the Advanced Mammalian Biomanufacturing Innovation Center ...
908 Devices (Nasdaq: MASS), a pioneer of purpose-built handheld and desktop devices for chemical and biomolecular analysis, is collaborating with UK-based, deep-tech innovation organization CPI on a project to optimize mammalian cell culture media and feeding strategies to improve g...
908 Devices Inc., (Nasdaq: MASS) a pioneer of purpose-built handheld and desktop mass spec devices for chemical and biomolecular analysis, today announced it will report financial results for the first quarter 2022 before market open on Tuesday, May 10, 2022. Company management will web...
908 Devices (NASDAQ: MASS) was a standout healthcare stock on Tuesday. The company's shares bounced more than 15% higher after it unveiled its latest set of quarterly results. 908 Devices, a niche healthcare equipment maker that specializes in mass spectrometry instruments, ...
News, Short Squeeze, Breakout and More Instantly...
908 Devices Inc. (Nasdaq: MASS), a pioneer of purpose-built handheld and desktop devices for chemical analysis, has appointed Michele M. Leonhart, the former Administrator of the United States Drug Enforcement Administration (DEA), to serve on its Board of Directors effective immediately. Ms....
Updated technology enables first responders to identify and quantify approximately 5,000 substances in mere seconds for a swift and definitive response 908 Devices Inc. (Nasdaq: MASS), a pioneer of purpose-built handheld and desktop devices for chemical analysis, today announced an ...
2024-06-01 11:08:00 ET Stock Traders Daily has produced this trading report using a proprietary method. This methodology seeks to optimize the entry and exit levels to maximize results and limit risk, and it is also applied to Index options, ETFs, and futures for our subscribers. This...